Determining genetic stabilities of chimeric dengue vaccine candidates based on dengue 2 PDK-53 virus by sequencing and quantitative TaqMAMA

Journal of Virological Methods

Volumn 131, Issue 1, 2006, Pages 1-9

  Butrapet, Siritorn ^a   Kinney, Richard M ^a   Huang, Claire Y H ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; DENGUE VACCINE; LIVE VACCINE; VALINE;

ANIMAL CELL; ARTICLE; CHIMERA; CONTROLLED STUDY; DENGUE VIRUS; DRUG QUALITY; DRUG STABILITY; EVALUATION; GENE LOCUS; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC LINKAGE; GENETIC STABILITY; MICROBIAL POPULATION DYNAMICS; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; QUANTITATIVE ANALYSIS; REVERTANT; SENSITIVITY ANALYSIS; TAQMAN MISMATCH AMPLIFICATION MUTATION ASSAY; VERO CELL; VIRUS ATTENUATION; VIRUS STRAIN;

ANIMALS; ANTIGENS, VIRAL; CERCOPITHECUS AETHIOPS; DENGUE VIRUS; GENOMIC INSTABILITY; POLYMERASE CHAIN REACTION; REASSORTANT VIRUSES; RNA HELICASES; SEQUENCE ANALYSIS; SERIAL PASSAGE; SERINE ENDOPEPTIDASES; VACCINES, ATTENUATED; VERO CELLS; VIRAL NONSTRUCTURAL PROTEINS; VIRAL VACCINES;

ANIMALIA; DENGUE VIRUS;

EID: 28844441250     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2005.06.019     Document Type: Article

References (23)

1. J. Arroyo, C. Miller, J. Catalan, G.A. Myers, M.S. Ratterree, D.W. Trent, and T.P. Monath ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy J. Virol. 78 2004 12497 12507
2. H.G. Bae, A. Nitsche, A. Teichmann, S.S. Biel, and M. Niedrig Detection of yellow fever virus: a comparison of quantitative real-time PCR and plaque assay J. Virol. Methods 110 2003 185 191
3. N. Bhamarapravati, and Y. Sutee Live attenuated tetravalent dengue vaccine Vaccine 18 Suppl. 2 2000 44 47
4. N. Bhamarapravati, S. Yoksan, T. Chayaniyayothin, S. Angsubphakorn, and A. Bunyaratvej Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): clinical, immunological and biological responses in adult volunteers Bull. World Health Organ 65 1987 189 195
5. M. Bray, R. Men, and C.J. Lai Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge J. Virol. 70 1996 4162 4166
6. S. Butrapet, C.Y. Huang, D.J. Pierro, N. Bhamarapravati, D.J. Gubler, and R.M. Kinney Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5′ noncoding region and nonstructural proteins 1 and 3 J. Virol. 74 2000 3011 3019
7. S. Butrapet, J. Rabablert, S. Angsubhakorn, W. Wiriyarat, C. Huang, R. Kinney, S. Punyim, and N. Bhamarapravati Chimeric dengue type 2/type 1 viruses induce immune responses in cynomolgus monkeys Southeast Asian J. Trop. Med. Public Health 33 2002 589 599
8. R.S. Cha, H. Zarbl, P. Keohavong, and W.G. Thilly Mismatch amplification mutation assay (MAMA): application to the c-H-ras gene PCR Methods Appl. 2 1992 14 20
9. A.P. Durbin, R.A. Karron, W. Sun, D.W. Vaughn, M.J. Reynolds, J.R. Perreault, B. Thumar, R. Men, C.J. Lai, W.R. Elkins, R.M. Chanock, B.R. Murphy, and S.S. Whitehead Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3′-untranslated region Am. J. Trop. Med. Hyg. 65 2001 405 413
10. W.E. Glaab, and T.R. Skopek A novel assay for allelic discrimination that combines the fluorogenic 5′ nuclease polymerase chain reaction (TaqMan) and mismatch amplification mutation assay Mutat. Res. 430 1999 1 12
11. F. Guirakhoo, K. Pugachev, Z. Zhang, G. Myers, I. Levenbook, K. Draper, J. Lang, S. Ocran, F. Mitchell, M. Parsons, N. Brown, S. Brandler, C. Fournier, B. Barrere, F. Rizvi, A. Travassos, R. Nichols, D. Trent, and T. Monath Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates J. Virol. 78 2004 4761 4775
12. C.Y.-H. Huang, S. Butrapet, D.J. Pierro, G.J. Chang, A.R. Hunt, N. Bhamarapravati, D.J. Gubler, and R.M. Kinney Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine J. Virol. 74 2000 3020 3028
13. C.Y.-H. Huang, S. Butrapet, K.R. Tsuchiya, N. Bhamarapravati, D.J. Gubler, and R.M. Kinney Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development J. Virol. 77 2003 11436 11447
14. C.Y.-H. Huang, S.J. Silengo, M.C. Whiteman, and R.M. Kinney Chimeric dengue 2 PDK-53/West Nile NY99 viruses retain the phenotypic attenuation markers of the candidate PDK-53 vaccine virus and protect Mice against lethal challenge with West Nile virus J. Virol. 2005
15. R.M. Kinney, S. Butrapet, G.J. Chang, K.R. Tsuchiya, J.T. Roehrig, N. Bhamarapravati, and D.J. Gubler Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53 Virology 230 1997 300 308
16. C.J. Lai, and T.P. Monath Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis Adv. Virus Res. 61 2003 469 509
17. B.R. Miller, and C.J. Mitchell Passage of yellow fever virus: its effect on infection and transmission rates in Aedes aegypti Am. J. Trop. Med. Hyg. 35 1986 1302 1309
18. T.P. Monath, F. Guirakhoo, R. Nichols, S. Yoksan, R. Schrader, C. Murphy, P. Blum, S. Woodward, K. McCarthy, D. Mathis, C. Johnson, and P. Bedford Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen J. Infect. Dis. 188 2003 1213 1230
19. A.G. Pletnev, M.S. Claire, R. Elkins, J. Speicher, B.R. Murphy, and R.M. Chanock Molecularly engineered live-attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus Virology 314 2003 190 195
20. A.G. Pletnev, R. Putnak, J. Speicher, E.J. Wagar, and D.W. Vaughn West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy Proc. Natl. Acad. Sci. U.S.A. 99 2002 3036 3041
21. Y.Z. Qiang, T. Qin, W. Fu, W.P. Cheng, Y.S. Li, and G. Yi Use of a rapid mismatch PCR method to detect gyrA and parC mutations in ciprofloxacin-resistant clinical isolates of Escherichia coli J. Antimicrob. Chemother. 49 2002 549 552
22. Z. Sultan, S. Nahar, B. Wretlind, E. Lindback, and M. Rahman Comparison of mismatch amplification mutation assay with DNA sequencing for characterization of fluoroquinolone resistance in Neisseria gonorrhoeae J. Clin. Microbiol. 42 2004 591 594
23. S. Yoksan, N. Bhamarapravati, and S.B. Halstead Dengue virus vaccine development study on biological markers of uncloned dengue 1-4 viruses serially passaged in primary dog kidney cells Proceeding of Fourth Symposium 1986 35 38